| Pulse Biosciences is a bioelectric medicine company. The CellFX® System (CellFX) is the commercial product to harness the distinctive advantages of Co.'s proprietary Nano-Pulse Stimulation (NPS) technology, such as the ability to non-thermally clear cells while sparing non-cellular tissue, to treat a variety of conditions for which an optimal solution remains unfulfilled. The CellFX System is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. Co. has also designed an integrated cloud software infrastructure called CellFX CloudConnect. CellFX CloudConnect also facilitates direct connectivity to the CellFX System. The PLSE average annual return since 2016 is shown above.
The Average Annual Return on the PLSE average annual return since 2016 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether PLSE average annual return since 2016 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PLSE average annual return calculation with any dividends reinvested as applicable (on ex-dates).